Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FRRL9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $10,485
Award facts
- Contract value 100% obligated
- $10,484.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $10,484.64 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 300 mg/2 mL Xolair (omalizumab) auto-injector units. This delivery order, with an ultimate completion date of February 5, 2026, carries no set-aside designation and represents a discrete purchase under DMS Pharmaceutical Group's broader prime vendor relationship with DLA. The award funds pharmaceutical supply needs for Department of Defense healthcare operations, leveraging DMS Pharmaceutical Group's established distribution capabilities for specialty biologics and immunosuppressant medications to military medical facilities.
This delivery order operates under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion acquisition strategy. The parent IDC, valued at $499,999,999 with a completion date of December 31, 2036, authorizes DLA to issue firm fixed-price delivery orders for diverse pharmaceutical products including branded and generic prescription drugs, biologics, and medical consumables to support military healthcare worldwide. DMS Pharmaceutical Group's demonstrated performance across numerous delivery orders and its extensive product portfolio—spanning oncology treatments, vaccines, specialty pharmaceuticals, and emergency medications—positions the company as a critical regional supplier within the Department of Defense's global pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DR26FRRL9?
SPE2DR26FRRL9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 14, 2026.
How much is contract SPE2DR26FRRL9 worth?
The government has obligated $10,485 on SPE2DR26FRRL9.
Is contract SPE2DR26FRRL9 an order under another contract?
Yes. SPE2DR26FRRL9 is a delivery order under SPE2DR25D9238, an indefinite delivery contract.
Was contract SPE2DR26FRRL9 competed?
The extent of competition for SPE2DR26FRRL9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award